Importantly, short PFS was observed in a large portion of advanced NSCLC patients after EGFR-TKIs therapy.2,3 Therefore, it is essential to declare biological mechanisms responsible for the development of EGFR-TKIs resistance in NSCLC. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.